Yesterday, China's National Food and Drug Administration issued 9 drug approval documents to be received. Among them, China Shandong Luye Pharmaceutical Co., Ltd.'s pantoprazole sodium for injection has been reviewed, adding another member to the 2.8 billion generic drug army.

Pantoprazole sodium was developed by Necomim, Germany. It is a new generation of proton pump inhibitor (PPI) after omeprazole and lansoprazole, and is a first-line treatment for peptic ulcer disease. This product inhibits the final step of gastric acid production by covalently binding with the two sites of the H+-K+-ATPase system of gastric parietal cells. This effect is dose-dependent and inhibits gastric acid secretion in both basic and stimulated states.

Compared with omeprazole and lansoprazole, pantoprazole sodium has a strong ability to inhibit acid, and when used in combination with other drugs, it has the advantage of small drug interaction; the metabolic pathway of pantoprazole sodium can pass through the The II enzyme system is carried out, so that the competitive action of the drug metabolism enzyme system is not prone to occur, and the interaction between drugs in the body is reduced.

In 2018, China's public medical institutions had sales of nearly 40 billion yuan in end-treatment peptic ulcer drugs, an increase of 2.33% year-on-year, and sales of pantoprazole sodium for injection were 7.913 billion yuan, occupying the leading position in the competitive landscape of digestive system and metabolic drugs. status.

At present, the main dosage forms of pantoprazole marketed in China are injections, enteric-coated tablets and enteric-coated capsules, among which injections are the most widely used in clinical practice. According to statistics, the sales of Hemitoprazole Sodium for Injection in hospitals across the country reached a maximum of 7.1 billion, and although it continued to decline, it will still have a huge sales market of 2.8 billion by 2020.

At present, as Pantoprazole Sodium, as a product in China's National Medical Insurance Catalogue and Essential Drug Catalogue, our company can provide high-quality imported raw materials and support binding declarations. Welcome to consult and cooperate.